Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA

Publisher： John Wiley & Sons Inc

E-ISSN： 1860-7187|13|1|30-36

ISSN： 1860-7179

Source： CHEMMEDCHEM, Vol.13, Iss.1, 2018-01, pp. : 30-36

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tumor Targeting: Dual Targeted Immunotherapy via In Vivo Delivery of Biohybrid RNAi‐Peptide Nanoparticles to Tumor‐Associated Macrophages and Cancer Cells (Adv. Funct. Mater. 27/2015)

By  

ADVANCED FUNCTIONAL MATERIALS, Vol. 25, Iss. 27, 2015-07 ,pp. : 4173-4173

John Wiley & Sons Inc

Access to resources Recommend Favorite

Targeting Human C‐Type Lectin‐like Molecule‐1 (CLL1) with a Bispecific Antibody for Immunotherapy of Acute Myeloid Leukemia

By  

ANGEWANDTE CHEMIE INTERNATIONAL EDITION, Vol. 53, Iss. 37, 2014-09 ,pp. : 9841-9845

John Wiley & Sons Inc

Access to resources Recommend Favorite

Targeting Human C‐Type Lectin‐like Molecule‐1 (CLL1) with a Bispecific Antibody for Immunotherapy of Acute Myeloid Leukemia

By  

ANGEWANDTE CHEMIE, Vol. 126, Iss. 37, 2014-09 ,pp. : 9999-10003

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dual Targeted Immunotherapy via In Vivo Delivery of Biohybrid RNAi‐Peptide Nanoparticles to Tumor‐Associated Macrophages and Cancer Cells

By  

ADVANCED FUNCTIONAL MATERIALS, Vol. 25, Iss. 27, 2015-07 ,pp. : 4183-4194

John Wiley & Sons Inc

Access to resources Recommend Favorite

Robust Prediction of Personalized Cell Recognition from a Cancer Population by a Dual Targeting Nanoparticle Library

By  

ADVANCED FUNCTIONAL MATERIALS, Vol. 25, Iss. 44, 2015-11 ,pp. : 6927-6935

John Wiley & Sons Inc

Access to resources Recommend Favorite